16 results about "Cardiac hypertrophy" patented technology

The invention belongs to the technical field of biological medicine and molecular biology, and provides a hypertrophic cardiomyopathy virulence gene MYH7c.794Cgt; the invention relates to T (p.Thr265Ile) and an application thereof. The MYH7 gene mutation is located on the ninth exon, the 794th base is mutated from C to T, namely ACC is mutated to ATC, and the 265th amino acid in the coded amino acid sequence is mutated from threonine to isoleucine. The mutation induces cardiac hypertrophy by disrupting energy metabolism-this defect occurs prior to the occurrence of systolic dysfunction. Along with increasingly prominent status of precision medicine in cardiovascular treatment, a treatment strategy aiming at an upstream pathological process (such as energy homeostasis and mitochondrial dysfunction) provides a way with a wide prospect for preventing and treating MYH7-related hypertrophic cardiomyopathy. MYH7 gene screening has important values in the aspects of promoting early diagnosis, guiding timely treatment intervention and realizing risk-based prevention and management.

The invention discloses a PARP1 inhibitor with methyl-1 'H-spiro [piperidine-4, 2'-quinazoline]-4 '(3' H)-ketone as a mother nucleus and a preparation method and application of the PARP1 inhibitor, a main compound has good PARP1 inhibitory activity (IC50 is at a submicromole level), and compared with a PARP1 inhibitor olaparib on the market, the compound has better anti-myocardial hypertrophy activity, and can be used for preparing a medicine for treating myocardial hypertrophy. The potential of PARP1 as a target spot for treating cardiac hypertrophy is proved, and a potential therapeutic drug is provided for treating cardiac hypertrophy.

The present invention provides small molecule PAK1 (P21 Activated Kinase 1) and / or PAK2 (P21 Activated Kinase 2) activators and their use in the prevention and / or treatment of diseases or conditions responsive to PAK1 and / or PAK2 activity or diseases or conditions associated with PAK1 and / or PAK2 inactivity, e.g. cardiovascular diseases or conditions, including cardiac fibrosis, cardiac hypertrophy, cardiac arrhythmias, heart failure and ischaemia / reperfusion injury.

The invention provides application of dragon's blood and active ingredients thereof in preparation of a medicine for treating heart failure, and belongs to the technical field of biological medicine. It is found for the first time that the dragon's blood can significantly improve the heart function of a heart failure model animal, reduce the level of a heart failure marker and relieve cardiac hypertrophy, cardiac pulmonary edema, myocarditis infiltration and fibrosis; core active components such as genistein and 3-hydroxycinnamic acid are screened and verified, wherein the genistein can reproduce the overall treatment effect of the dragon's blood. The invention also discloses that the core action mechanism of the composition is to promote macrophage VEGFC secretion, increase heart lymphatic vessel density and promote lymphatic vessel neogenesis, and a brand new natural drug candidate scheme and an intervention strategy are provided for heart failure treatment.

The invention belongs to the technical field of biological medicines, and discloses a cardiac function enhancer and application thereof. The active ingredient of the cardiac function enhancer is polyunsaturated phosphatidyl ethanolamine or 3-denitrified adenosine. The polyunsaturated phosphatidyl ethanolamine can be directly used as a key lipid for enhancing the cardiac function. And 2, 3-denitrified adenosine competitively inhibits phosphatidyl ethanolamine methyltransferase to reduce the conversion of phosphatidyl ethanolamine to phosphatidylcholine, so that the level of endogenous polyunsaturated phosphatidyl ethanolamine is improved, and the same effect is indirectly achieved. The invention provides application of the active ingredients in preparation of medicines or nutritional supplements for treating heart diseases, preventing and inhibiting cardiac hypertrophy and improving heart functions.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a modified Zhenwu decoction traditional Chinese medicine compound and application thereof. The traditional Chinese medicine compound of the modified true Wu decoction is prepared from the following raw materials in parts by weight: 10 to 30 parts of radix aconiti lateralis praeparata slices, 6 to 18 parts of sun-dried ginseng, 10 to 30 parts of poria cocos, 8 to 24 parts of raw rhizoma atractylodis macrocephalae, 10 to 30 parts of radix paeoniae alba, 20 to 60 parts of pubescent holly root and 4 to 12 parts of rhodiola rosea. Clinical observation finds that the flavored Zhenwu decoction is an effective drug for resisting HFpEF, and can reverse cardiac hypertrophy of HFpEF mice, relieve pulmonary edema conditions, remarkably improve the diastolic function, improve HFpEF cardiac hypertrophy, improve cardiac diastolic dysfunction, improve myocardial injury and collagen deposition and improve myocardial cell mitochondrial injury.

The invention discloses an application of Gitogenin (Gitogenin, GIT) in preparation of a medicine for preventing or treating hypertrophic cardiomyopathy and diseases caused by the hypertrophic cardiomyopathy. According to the application disclosed by the invention, the prevention or treatment of the hypertrophic cardiomyopathy by the Gitogenin is proposed for the first time, and experiments find that the in-vitro treatment of the Gitogenin can obviously inhibit the phenotype of myocardial cell hypertrophy; gitogenin is applied to gavage treatment on a mouse with hereditary hypertrophic cardiomyopathy caused by gene mutation, and the Gitogenin is found to obviously relieve pathological cardiac hypertrophy of the mouse and improve the cardiac function. The Gitogenin can be used for preparing the medicine for resisting the hereditary hypertrophic cardiomyopathy, and a new way and means are provided for treating the hypertrophic cardiomyopathy; in addition, the Gitogenin is clearly reported to be a main natural steroid component separated from a whole plant of a plant Tribulus longipetaus (a caltrop plant), the biological safety of the Gitogenin to organisms is high, and the Gitogenin has a good application prospect in clinic.

The present application relates to a kind of compound for treating myocardial hypertrophy disease, it is related to the field of biological medicine.The compound can effectively improve the left ventricular systolic function of myocardial hypertrophy mouse, reduce heart weight / body weight, lung weight / body weight, myocardial cell cross-sectional area and fibrosis;Meanwhile, the compound can relieve angiotensin II induced myocardial hypertrophy in vitro.Especially, the compound can improve the damage and dysfunction of mitochondria in myocardial tissue of myocardial hypertrophy mouse, while improving the oxidative phosphorylation level of myocardial cell after angiotensin II stimulation, has the potential of preparation treatment myocardial mitochondrial damage, inhibits myocardial cell hypertrophy, treatment myocardial hypertrophy and heart failure drug.

A pharmaceutical composition containing an effective amount of cannabidiol (CBD) for use in the treatment or prevention of cardiac conditions, as well as related methods and uses. [Solution] Cardiac conditions include heart failure, acute myocarditis, toxicity caused by anticancer therapy, acute pericarditis, cardiac sarcoidosis, inflammatory cardiomyopathy, and atherosclerosis, as well as related uses and methods. This disclosure shows that CBD is effective in (i) reducing cardiac hypertrophy; (ii) reducing cardiac fibrosis; (iii) reducing BNP levels; (iv) reducing cytokine IL1β levels; (v) reducing cytokine IL6 levels; (vi) reducing CD69 levels; (vii) increasing cytokine IL10 levels; and (viii) combinations thereof. The compositions are preferably adapted for parenteral administration.

The application belongs to the field of medicine, and specifically discloses application of a small molecule compound KA-C1 in preparation of a medicine for preventing or treating cardiac hypertrophy, cardiac fibrosis and / or heart failure. The application finds that kynurenine-3-monooxygenase (KMO) is an effective medicine target for treating pathological cardiac hypertrophy and cardiac fibrosis through research. Through computer-aided virtual screening, the application finds a KMO-specific agonist KA-C1, and KA-C1, as a medicine active ingredient, can directly stimulate KMO protein activity, thereby effectively resisting pathological cardiac hypertrophy and cardiac fibrosis, and further preventing or treating heart failure. Therefore, the discovery of the small molecule compound KA-C1 provides a new medicine target strategy for treating pathological cardiac hypertrophy, cardiac fibrosis and heart failure, and has important and wide application prospects.

The application discloses application of 1,2,3,4,6-O-galloyl glucose in preparation of a drug for preventing and / or treating myocardial hypertrophy, and belongs to the technical field of biological medicine. The application proves for the first time that PGG can significantly improve cardiac dysfunction induced by TAC operation, inhibit increase of heart volume and weight, myocardial cell hypertrophy, down-regulate expression of myocardial hypertrophy markers Nppa, Nppb and Myh7, and block excessive activation of an AKT / ERK signal path. Therefore, PGG can effectively prevent and / or treat pathological myocardial hypertrophy, and has a clear clinical application prospect.

A method for reducing pathological cardiac hypertrophy and / or inducing physiological cardiac hypertrophy by administering Nigella sativa or an extract thereof to a subject in need thereof, especially to an athletic subject in order to reduce exercise-induced pathological cardiac hypertrophy. A composition comprising Nigella sativa for use in said method.

The invention relates to application of an SOAT1 inhibitor in preparation of drugs for preventing and treating myocardial hypertrophy related diseases, and belongs to the technical field of biological medicines. The invention provides application of an SOAT1 inhibitor in preparation of drugs for preventing and treating myocardial hypertrophy related diseases. The relationship between the SOAT1 gene and cardiac hypertrophy is found, the mechanism of the SOAT1 gene and cardiac hypertrophy is further elaborated, and by inhibiting the activity of the SOAT1 gene or the protein of the SOAT1 gene, the heart size is recovered, the cross sectional area of cardiac muscle cells is remarkably inhibited, myocardial fibrosis is improved, and the disease progress of pathological cardiac hypertrophy is restrained. The invention also provides an SOAT1 inhibitor, which comprises a small molecule compound F0808-1832, so as to inhibit SOAT1 gene expression and protein activity, lay a solid theoretical basis for preventing and treating myocardial hypertrophy related diseases, and provide a medicine with a good treatment effect.

A method of treating a subject with a disease where the disease is selected from the group consisting of hypertension, cardiac hypertrophy, cardiomyocyte enlargement, myocardial fibrosis, liver fibrosis, and cardiac fibrosis is provided. The method involves administering to the subject an effective amount of a fibroblast growth factor (FGF) 21 inhibitor.

The invention discloses a photo-activated myocardial targeting nano capsule for heart failure, and belongs to the technical field of biological medicines and nano materials. The nanometer capsule-like body comprises an inner core which is a nanometer capsule-like body unit, is obtained by nanocrystallization of a plant capsule-like body film and retains photoreaction activity; the shell is a bionic coating layer derived from a myocardial cell membrane. The invention also provides a preparation method of the nano capsule-like body and application of the nano capsule-like body in preparation of medicines for treating pressure load related cardiomyopathy (such as heart failure, cardiac hypertrophy and fibrosis). According to the nanometer cystoid, myocardial targeted enrichment is achieved through myocardial cell membrane coating, ATP is controllably generated under specific red light irradiation, myocardial cell energy metabolism defects are repaired, the mitochondrial function is improved, and therefore myocardial hypertrophy and fibrosis are effectively inhibited on cell and animal models, and the heart function is improved. The invention provides a novel energy metabolism repairing strategy which is triggered on demand and controllable in dosage for heart failure treatment.

The invention belongs to the technical field of medicines for treating myocardial hypertrophy, and discloses a pharmaceutical composition containing benzoyl mesaconitine and paeoniflorin and application thereof.The pharmaceutical composition is characterized by comprising benzoyl mesaconitine or pharmaceutical salt thereof and paeoniflorin or pharmaceutical salt thereof as active ingredients, the molar ratio of benzoyl mesaconitine to paeoniflorin is 1: 1000-1000: 1, preferably 5: 1000, and the molar ratio of benzoyl mesaconitine to paeoniflorin is 1: 1000-1000. Cell experiment results show that the composition can play a remarkable synergistic effect in the process of intervening angiotensin II induced myocardial cell hypertrophy, the effect of the composition is superior to that of a single component, the oxidative stress level of cells can be effectively relieved, and the curative effect of the composition is improved. The invention provides a new generation of medicine scheme with definite components and remarkable effect for clinical treatment of myocardial hypertrophy, can be used for preparing various dosage forms such as tablets, capsules and injections, and has important clinical transformation value and application prospect.